{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:47:21Z","timestamp":1793195241314,"version":"4.5.0"},"reference-count":78,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Wilkes Melanoma Foundation grant"},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K01AI163412"],"award-info":[{"award-number":["K01AI163412"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,5,7]]},"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Management of immune-related adverse events (irAEs) is important as they cause treatment interruption or discontinuation, more often seen with combination immune checkpoint inhibitor (ICI) therapy. Here, we retrospectively evaluated the safety and effectiveness of anti-interleukin-6 receptor (anti-IL-6R) as therapy for irAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective multicenter study evaluating patients diagnosed with de novo irAEs or flare of pre-existing autoimmune disease following ICI and were treated with anti-IL-6R. Our objectives were to assess the improvement of irAEs as well as the overall tumor response rate (ORR) before and after anti-IL-6R treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified a total of 92 patients who received therapeutic anti-IL-6R antibodies (tocilizumab or sarilumab). Median age was 61 years, 63% were men, 69% received anti-programmed cell death protein-1 (PD-1) antibodies alone, and 26% patients were treated with the combination of anti-cytotoxic T lymphocyte antigen-4 and anti-PD-1 antibodies. Cancer types were primarily melanoma (46%), genitourinary cancer (35%), and lung cancer (8%). Indications for using anti-IL-6R antibodies included inflammatory arthritis (73%), hepatitis\/cholangitis (7%), myositis\/myocarditis\/myasthenia gravis (5%), polymyalgia rheumatica (4%), and one patient each with autoimmune scleroderma, nephritis, colitis, pneumonitis and central nervous system vasculitis. Notably, 88% of patients had received corticosteroids, and 36% received other disease-modifying antirheumatic drugs (DMARDs) as first-line therapies, but without adequate improvement. After initiation of anti-IL-6R (as first-line or post-corticosteroids and DMARDs), 73% of patients showed resolution or change to \u2264grade 1 of irAEs after a median of 2.0 months from initiation of anti-IL-6R therapy. Six patients (7%) stopped anti-IL-6R due to adverse events. Of 70 evaluable patients by RECIST (Response Evaluation Criteria in Solid Tumors) V.1.1 criteria; the ORR was 66% prior versus 66% after anti-IL-6R (95%\u2009CI, 54% to 77%), with 8% higher complete response rate. Of 34 evaluable patients with melanoma, the ORR was 56% prior and increased to 68% after anti-IL-6R (p=0.04).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Targeting IL-6R could be an effective approach to treat several irAE types without hindering antitumor immunity. This study supports ongoing clinical trials evaluating the safety and efficacy of tocilizumab (anti-IL-6R antibody) in combination with ICIs (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04940299\">NCT04940299<\/jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03999749\">NCT03999749<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2023-006814","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T13:32:05Z","timestamp":1686922325000},"page":"e006814","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":106,"title":["Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct04940299","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03999749","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03601611","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03293784","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04940299","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04375228","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03601611","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03999749","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03821246","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04524871","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03424005","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03869190","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Faisal","family":"Fa'ak","sequence":"first","affiliation":[{"name":"Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Buni","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adewunmi","family":"Falohun","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Lu","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhee","family":"Song","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H","family":"Johnson","sequence":"additional","affiliation":[{"name":"Ochsner Health, New Orleans, Louisiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrystia M","family":"Zobniw","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van A","family":"Trinh","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Osama","family":"Awiwi","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourel Hoda","family":"Tahon","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled M","family":"Elsayes","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaysia","family":"Ludford","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma J","family":"Montazari","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Chernis","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center at Houston John P and Katherine G McGovern Medical School, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Dimitrova","sequence":"additional","affiliation":[{"name":"Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Sandigursky","sequence":"additional","affiliation":[{"name":"Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Sparks","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Abu-Shawer","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Rahma","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Thanarajasingam","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley M","family":"Zeman","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafee","family":"Talukder","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Singh","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah H","family":"Chung","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-3394","authenticated-orcid":false,"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Daher","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala","family":"Abudayyeh","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Osman","sequence":"additional","affiliation":[{"name":"Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4962-2957","authenticated-orcid":false,"given":"Jeffrey","family":"Weber","sequence":"additional","affiliation":[{"name":"Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean H","family":"Tayar","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E","family":"Suarez-Almazor","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha","family":"Abdel-Wahab","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Assiut University Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0153-0244","authenticated-orcid":false,"given":"Adi","family":"Diab","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"2025100303040231000_11.6.e006814.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"2025100303040231000_11.6.e006814.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60958-2"},{"key":"2025100303040231000_11.6.e006814.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131"},{"key":"2025100303040231000_11.6.e006814.4","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical activity and safety of the anti-programmed death 1 Monoclonal antibody Dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: A Nonrandomized phase 1 clinical trial","volume":"6","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100303040231000_11.6.e006814.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9761"},{"key":"2025100303040231000_11.6.e006814.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30364-3"},{"key":"2025100303040231000_11.6.e006814.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00561-4"},{"key":"2025100303040231000_11.6.e006814.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2025100303040231000_11.6.e006814.9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune Checkpoint blockade in patients with cancer: A systematic review of case reports","volume":"11","author":"Abdel-Wahab","year":"2016","journal-title":"PLoS One"},{"key":"2025100303040231000_11.6.e006814.10","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"2025100303040231000_11.6.e006814.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.09.002"},{"key":"2025100303040231000_11.6.e006814.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"2025100303040231000_11.6.e006814.13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367"},{"key":"2025100303040231000_11.6.e006814.14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100303040231000_11.6.e006814.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"2025100303040231000_11.6.e006814.16","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0020"},{"key":"2025100303040231000_11.6.e006814.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"2025100303040231000_11.6.e006814.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"2025100303040231000_11.6.e006814.19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002261","article-title":"Timing of steroid initiation and response rates to immune Checkpoint inhibitors in metastatic cancer","volume":"9","author":"Maslov","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100303040231000_11.6.e006814.20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629"},{"key":"2025100303040231000_11.6.e006814.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0352-8"},{"key":"2025100303040231000_11.6.e006814.22","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217745144"},{"key":"2025100303040231000_11.6.e006814.23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejim.2021.07.016","article-title":"Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series","volume":"93","author":"Campochiaro","year":"2021","journal-title":"Eur J Intern Med"},{"key":"2025100303040231000_11.6.e006814.24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejca.2021.08.031","article-title":"Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy","volume":"157","author":"Dimitriou","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025100303040231000_11.6.e006814.25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005111","article-title":"COLAR: open-label clinical study of IL-6 blockade with Tocilizumab for the treatment of immune Checkpoint inhibitor-induced colitis and arthritis","volume":"10","author":"Holmstroem","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100303040231000_11.6.e006814.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(02)00210-9"},{"key":"2025100303040231000_11.6.e006814.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.04.004"},{"key":"2025100303040231000_11.6.e006814.28","doi-asserted-by":"crossref","unstructured":"Kim ST , Chu Y , Misoi M , et al . Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 2022;13.doi:10.1038\/s41467-022-29539-3","DOI":"10.1038\/s41467-022-29539-3"},{"key":"2025100303040231000_11.6.e006814.29","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/keab438","article-title":"Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept","volume":"61","author":"Rempenault","year":"2022","journal-title":"Rheumatology"},{"key":"2025100303040231000_11.6.e006814.30","doi-asserted-by":"publisher","DOI":"10.1038\/nature04753"},{"key":"2025100303040231000_11.6.e006814.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.07.035"},{"key":"2025100303040231000_11.6.e006814.32","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3794"},{"key":"2025100303040231000_11.6.e006814.33","unstructured":"Administration USFaD . Drugs@FDA: FDA-approved drugs: U.S Department of health and human services. 2022. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125276s134lbl.pdf"},{"key":"2025100303040231000_11.6.e006814.34","unstructured":"Administration USFaD . Drugs@FDA: FDA-approved drugs: U.S Department of health and human services. 2018. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761037s001lbl.pdf"},{"key":"2025100303040231000_11.6.e006814.35","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00432-021-03750-z","article-title":"Analysis of Cytokines in serum and Bronchoalveolar Lavage fluid in patients with immune-Checkpoint inhibitor-associated Pneumonitis: a cross-sectional case-control study","volume":"148","author":"Kowalski","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025100303040231000_11.6.e006814.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2016.12.019"},{"key":"2025100303040231000_11.6.e006814.37","unstructured":"Zhou X , Jaquith J , Li Y . Inflammatory arthritis induced by immune Checkpoint inhibitor therapy: a distinct clinical entity and immunologic phenotype arthritis. Rheumatol 2019;71."},{"key":"2025100303040231000_11.6.e006814.38","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.2505","article-title":"Evaluation of serum IL-17 levels during Ipilimumab therapy: correlation with colitis","volume":"29","author":"Callahan","year":"2011","journal-title":"JCO"},{"key":"2025100303040231000_11.6.e006814.39","doi-asserted-by":"crossref","first-page":"15542","DOI":"10.18632\/oncotarget.24509","article-title":"Serum levels of soluble Cd163 and Cxcl5 may be predictive markers for immune-related adverse events in patients with advanced Melanoma treated with Nivolumab: a pilot study","volume":"9","author":"Fujimura","year":"2018","journal-title":"Oncotarget"},{"key":"2025100303040231000_11.6.e006814.40","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-018-1467-x","article-title":"Sex and Interleukin-6 are Prognostic factors for autoimmune toxicity following treatment with anti-Ctla4 blockade","volume":"16","author":"Valpione","year":"2018","journal-title":"J Transl Med"},{"key":"2025100303040231000_11.6.e006814.41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2795"},{"key":"2025100303040231000_11.6.e006814.42","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s00262-021-02855-1","article-title":"Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors","volume":"70","author":"Tyan","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2025100303040231000_11.6.e006814.43","doi-asserted-by":"publisher","DOI":"10.1172\/JCI57158"},{"key":"2025100303040231000_11.6.e006814.44","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0412-0","article-title":"Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related Enterocolitis","volume":"6","author":"Johnson","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2025100303040231000_11.6.e006814.45","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.2169\/internalmedicine.5216-20","article-title":"Infliximab was found to be effective for treating immunosuppressive drug-resistant hepatitis due to Durvalumab","volume":"59","author":"Nakashima","year":"2020","journal-title":"Intern Med"},{"key":"2025100303040231000_11.6.e006814.46","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/art.41604","article-title":"Inflammatory Myositis in cancer patients receiving immune Checkpoint inhibitors","volume":"73","author":"Aldrich","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025100303040231000_11.6.e006814.47","doi-asserted-by":"crossref","unstructured":"Safa H , Johnson DH , Trinh VA , et al . Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 2019;7.doi:10.1186\/s40425-019-0774-y","DOI":"10.1186\/s40425-019-0774-y"},{"key":"2025100303040231000_11.6.e006814.48","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1877415","article-title":"Infliximab for the treatment of patients with Checkpoint inhibitor-associated acute tubular interstitial nephritis","volume":"10","author":"Lin","year":"2021","journal-title":"Oncoimmunology"},{"key":"2025100303040231000_11.6.e006814.49","doi-asserted-by":"crossref","unstructured":"Huang S , Jordan A , Jenneman D , et al . Rapid improvement following receipt of infliximab in steroid-refractory Durvalumab-associated grade 3 pneumonitis. Cureus 2022;20.doi:10.7759\/cureus.22295","DOI":"10.7759\/cureus.22295"},{"key":"2025100303040231000_11.6.e006814.50","doi-asserted-by":"crossref","DOI":"10.3892\/mco.2021.2227","article-title":"Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study","volume":"14","author":"Kadokawa","year":"2021","journal-title":"Mol Clin Oncol"},{"key":"2025100303040231000_11.6.e006814.51","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcr\/ytab002","article-title":"Refractory Constrictive Pericarditis caused by an immune Checkpoint inhibitor properly managed with Infliximab: a case report","volume":"5","author":"Moriyama","year":"2021","journal-title":"Eur Heart J Case Rep"},{"key":"2025100303040231000_11.6.e006814.52","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001887","article-title":"Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis","volume":"8","author":"Cautela","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100303040231000_11.6.e006814.53","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1159\/000510740","article-title":"Immune checkpoint inhibitor-induced polymyositis and myasthenia gravis with fatal outcome","volume":"13","author":"Giglio","year":"2020","journal-title":"Case Rep Oncol"},{"key":"2025100303040231000_11.6.e006814.54","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1159\/000511252","article-title":"Successful treatment of an immune-mediated colitis induced by checkpoint inhibitor therapy in a patient with advanced melanoma","volume":"14","author":"Paparoupa","year":"2020","journal-title":"Case Rep Gastroenterol"},{"key":"2025100303040231000_11.6.e006814.55","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.1002\/hed.26455","article-title":"Recurrent audiovestibular dysfunction and associated neurological immune-related adverse events in a melanoma patient treated with nivolumab and ipilimumab","volume":"42","author":"Choi","year":"2020","journal-title":"Head Neck"},{"key":"2025100303040231000_11.6.e006814.56","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.3748\/wjg.v26.i16.1971","article-title":"Severe steroid refractory gastritis induced by nivolumab: a case report","volume":"26","author":"Vindum","year":"2020","journal-title":"World J Gastroenterol"},{"key":"2025100303040231000_11.6.e006814.57","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0471-2","article-title":"Infliximab for treatment-refractory transverse Myelitis following immune therapy and radiation","volume":"6","author":"Chang","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2025100303040231000_11.6.e006814.58","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.mayocpiqo.2017.07.004","article-title":"Brachial plexus neuritis associated with Anti-Programmed cell death-1 antibodies: report of 2 cases","volume":"1","author":"Alhammad","year":"2017","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"2025100303040231000_11.6.e006814.59","doi-asserted-by":"crossref","DOI":"10.1186\/s13256-018-1786-9","article-title":"Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report","volume":"12","author":"Kopeck\u00fd","year":"2018","journal-title":"J Med Case Rep"},{"key":"2025100303040231000_11.6.e006814.60","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216109"},{"key":"2025100303040231000_11.6.e006814.61","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.3390\/curroncol28030201","article-title":"Real world outcomes and hepatotoxicity of infliximab in the treatment of Steroid-Refractory immune-related adverse events","volume":"28","author":"Araujo","year":"2021","journal-title":"Curr Oncol"},{"key":"2025100303040231000_11.6.e006814.62","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1162-y"},{"key":"2025100303040231000_11.6.e006814.63","doi-asserted-by":"crossref","first-page":"700","DOI":"10.6004\/jnccn.2020.7647","article-title":"Association of chronic immune-mediated diarrhea and colitis with favorable cancer response","volume":"19","author":"Zou","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2025100303040231000_11.6.e006814.64","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001687","article-title":"Concomitant or delayed anti-TNF Differentially impact on immune-related adverse events and antitumor efficacy after anti-Cd40 therapy","volume":"8","author":"Jacoberger-Foissac","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100303040231000_11.6.e006814.65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3322"},{"key":"2025100303040231000_11.6.e006814.66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3449"},{"key":"2025100303040231000_11.6.e006814.67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2031717"},{"key":"2025100303040231000_11.6.e006814.68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02141"},{"key":"2025100303040231000_11.6.e006814.69","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Gord\u00f3n S\u00e1nchez FM , G\u00f3mez-Dom\u00ednguez E , Paredes Ruiz D , et al . Ustekinumab for corticodependent immune-mediated colitis by pembrolizumab, an alternative for patients with concomitant liver injury. Rev Esp Enferm Dig 2022.doi:10.17235\/reed.2022.8618\/2022","DOI":"10.17235\/reed.2022.8618\/2022"},{"key":"2025100303040231000_11.6.e006814.70","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jdcr.2021.03.029","article-title":"Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma","volume":"11","author":"Glinos","year":"2021","journal-title":"JAAD Case Reports"},{"key":"2025100303040231000_11.6.e006814.71","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1684\/ejd.2021.4087","article-title":"Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient","volume":"31","author":"Vinaixa Aranzazu","year":"2021","journal-title":"Eur J Dermatol"},{"key":"2025100303040231000_11.6.e006814.72","article-title":"A novel approach to the treatment of Pembrolizumab-induced psoriasis exacerbation: A case report","volume":"11","author":"Monsour","year":"2019","journal-title":"Cureus"},{"key":"2025100303040231000_11.6.e006814.73","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2217\/imt-2021-0274","article-title":"Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy","volume":"14","author":"Ma","year":"2022","journal-title":"Immunotherapy"},{"key":"2025100303040231000_11.6.e006814.74","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0682"},{"key":"2025100303040231000_11.6.e006814.75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1703047"},{"key":"2025100303040231000_11.6.e006814.76","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.868","article-title":"Successful management of severe bronchial asthma exacerbated by Anti\u2010PD\u2010L1 treatment: A report of two cases","volume":"9","author":"Sumi","year":"2021","journal-title":"Respirol Case Rep"},{"key":"2025100303040231000_11.6.e006814.77","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-020-01375-5","article-title":"Programmed cell Death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report","volume":"21","author":"Harada","year":"2021","journal-title":"BMC Pulm Med"},{"key":"2025100303040231000_11.6.e006814.78","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/jdv.17981","article-title":"Dupilumab ocular side effects in patients with Atopic dermatitis: a systematic review","volume":"36","author":"Neagu","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"}],"updated-by":[{"DOI":"10.1136\/jitc-2023-006814corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000}}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-006814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T10:04:18Z","timestamp":1759485858000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-006814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":78,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,16]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1136\/jitc-2023-006814"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-006814","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}